Diseases, Conditions, Syndromes

Short-course rifamycin-based regimens preferred for latent TB

(HealthDay)—For treatment of latent tuberculosis infection (LTBI), short-course rifamycin-based regimens are preferred over longer-course isoniazid monotherapy, according to guidelines published in the Feb. 14 issue of ...

Diseases, Conditions, Syndromes

New animal model shows effective treatment for latent tuberculosis

A major goal of tuberculosis (TB) research is to find a way to treat people with the latent (or inactive) form of the disease to keep them from developing symptomatic TB. A breakthrough study using a new animal model developed ...

Medical research

Peptide derived from fungi kills TB bacteria

The discovery of the peptide as a possible future antibiotic was made by researchers who screened different antimicrobial peptides' ability to prevent the growth of Mycobacterium tuberculosis. The peptide they found comes ...

Diseases, Conditions, Syndromes

Tuberculosis—Inhibiting host cell death with immunotherapy

Tuberculosis treatment still entails the administration of several antibiotics over a period of months and is torturous for many patients. The pathogen's increasing multidrug resistance additionally complicates this lengthy ...

Diseases, Conditions, Syndromes

New tuberculosis drug may shorten treatment time for patients

A new experimental antibiotic for tuberculosis has been shown to be more effective against TB than isoniazid, a decades-old drug which is currently one of the standard treatments. In mouse studies, the new drug showed a much ...

Medications

Researchers develop new tuberculosis treatment

Led by researchers at RCSI (Royal College of Surgeons in Ireland), a team of researchers has developed a new treatment for tuberculosis (TB). This work could offer a practical treatment that has the potential to be scaled-up ...

page 2 from 6